Alector, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Alector, Inc. (ALEC) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $2.61 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-06
- Alector, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $2.61M, a 63.04% decline year-over-year.
- Alector, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $2.91M, a 65.18% decline year-over-year.
- Alector, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $6.40M, a 29.14% decline year-over-year.
- Alector, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $7.06M, a 28.73% decline year-over-year.
- Alector, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $26.66M, a 32.45% decline from fiscal 2024.
- Alector, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $39.46M, a 7.79% decline from fiscal 2023.
- Alector, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $42.80M, a 7.26% decline from fiscal 2022.
- Alector, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $46.15M, a 13.14% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.61M 10-Q · filed 2026-08-06 | $5.52M derived: sum of 2 quarters · filed 2026-08-06 | ||
| 2026-03-31 | $2.91M 10-Q · filed 2026-08-06 | |||
| 2025-12-31 | $26.66M 10-K · filed 2026-02-25 | |||
| 2025-09-30 | $6.40M 10-Q · filed 2025-11-06 | $13.46M derived: sum of 2 quarters · filed 2026-08-06 | $21.82M derived: sum of 3 quarters · filed 2026-08-06 | |
| 2025-06-30 | $7.06M 10-Q · filed 2026-08-06 | $15.41M derived: sum of 2 quarters · filed 2026-08-06 | ||
| 2025-03-31 | $8.35M 10-Q · filed 2026-08-06 | |||
| 2024-12-31 | $39.46M 10-K · filed 2026-02-25 | |||
| 2024-09-30 | $9.04M 10-Q · filed 2025-11-06 | $18.94M derived: sum of 2 quarters · filed 2025-11-06 | $29.25M derived: sum of 3 quarters · filed 2025-11-06 | |
| 2024-06-30 | $9.91M 10-Q · filed 2025-11-06 | $20.22M derived: sum of 2 quarters · filed 2025-11-06 | ||
| 2024-03-31 | $10.31M 10-Q · filed 2025-11-06 | |||
| 2023-12-31 | $42.80M 10-K · filed 2025-02-26 | |||
| 2023-09-30 | $10.06M 10-Q · filed 2024-11-06 | $20.28M derived: sum of 2 quarters · filed 2024-11-06 | $31.26M derived: sum of 3 quarters · filed 2024-11-06 | |
| 2023-06-30 | $10.22M 10-Q · filed 2024-11-06 | $21.20M derived: sum of 2 quarters · filed 2024-11-06 | ||
| 2023-03-31 | $10.97M 10-Q · filed 2024-11-06 | |||
| 2022-12-31 | $46.15M 10-K · filed 2025-02-26 | |||
| 2022-09-30 | $10.77M 10-Q · filed 2023-11-07 | $23.24M derived: sum of 2 quarters · filed 2023-11-07 | $35.18M derived: sum of 3 quarters · filed 2023-11-07 | |
| 2022-06-30 | $12.48M 10-Q · filed 2023-11-07 | $24.42M derived: sum of 2 quarters · filed 2023-11-07 | ||
| 2022-03-31 | $11.94M 10-Q · filed 2023-11-07 | |||
| 2021-12-31 | $40.78M 10-K · filed 2024-02-27 | |||
| 2021-09-30 | $10.20M 10-Q · filed 2022-11-08 | $19.28M derived: sum of 2 quarters · filed 2022-11-08 | $28.08M derived: sum of 3 quarters · filed 2022-11-08 | |
| 2021-06-30 | $9.08M 10-Q · filed 2022-11-08 | $17.88M derived: sum of 2 quarters · filed 2022-11-08 | ||
| 2021-03-31 | $8.80M 10-Q · filed 2022-11-08 | |||
| 2020-12-31 | $30.52M 10-K · filed 2023-02-28 | |||
| 2020-09-30 | $8.03M 10-Q · filed 2021-11-04 | $14.98M derived: sum of 2 quarters · filed 2021-11-04 | $21.62M derived: sum of 3 quarters · filed 2021-11-04 | |
| 2020-06-30 | $6.95M 10-Q · filed 2021-11-04 | $13.59M derived: sum of 2 quarters · filed 2021-11-04 | ||
| 2020-03-31 | $6.64M 10-Q · filed 2021-11-04 | |||
| 2019-12-31 | $16.28M 10-K · filed 2022-02-24 | |||
| 2019-09-30 | $4.10M 10-Q · filed 2020-11-10 | $7.80M derived: sum of 2 quarters · filed 2020-11-10 | $11.04M derived: sum of 3 quarters · filed 2020-11-10 | |
| 2019-06-30 | $3.69M 10-Q · filed 2020-11-10 | $6.94M derived: sum of 2 quarters · filed 2020-11-10 | ||
| 2019-03-31 | $3.25M 10-Q · filed 2020-11-10 | |||
| 2018-12-31 | $6.92M 10-K · filed 2021-02-25 | |||
| 2018-09-30 | $1.98M 10-Q · filed 2019-11-12 | $3.14M derived: sum of 2 quarters · filed 2019-11-12 | $4.26M derived: sum of 3 quarters · filed 2019-11-12 | |
| 2018-06-30 | $1.16M 10-Q · filed 2019-11-12 | $2.29M derived: sum of 2 quarters · filed 2019-11-12 | ||
| 2018-03-31 | $1.12M 10-Q · filed 2019-11-12 | |||
| 2017-12-31 | $5.35M 10-K · filed 2020-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |